Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

2020 TTF AM SESSION - RAEZ - Agnostic Tumor Therapy - The Future of Lung Cancer Has Arrived
Targeted Therapies Patient Forum 2020, AM Session - Dr. Luis Raez - Agnostic Tumor Therapy - The Future of Lung Cancer Has Arrived
Author
Luis Raez, MD FACP FCCP
Image
We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum.

This year's live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute.

This day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer.

Access to the full agenda can be found here: https://drive.google.com/file/d/10sk1Are37fCIHcc6laD6lh9m_DjLF1ZX/view?u.... Full bios for attending faculty can be found here: https://docs.google.com/document/d/1EQEmBpOI-vNIywsFPEIhizql_Xnzjcf5-mua....

 

In this video from the AM Session of the event, Dr. Luis Raez discusses agnostic tumor therapy.

 

We thank our sponsors for their support of this event! AstraZeneca, Lilly, Novartis, Takeda, Foundation Medicine, Boehringer Ingelheim, Blueprint Medicines and Genentech

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora